Sera Prognostics Inc

NASDAQ SERA

Data sourced from

and

Download Data

Sera Prognostics Inc Debt to Equity Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending December 31, 2021

Sera Prognostics Inc Debt to Equity Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending December 31, 2021. The debt to equity ratio measures the proportion of a company's financing that comes from debt relative to shareholders' equity. It is calculated by dividing total debt by shareholders' equity. This ratio provides insights into the company's capital structure and the degree of financial leverage. A higher ratio suggests a higher level of debt financing in relation to equity. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Sera Prognostics Inc Debt to Equity Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -0.04.

NASDAQ: SERA

Sera Prognostics Inc

CEO	Dr. Gregory C. Critchfield M.D., M.S.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees	55
Sector	Healthcare
Industry	Diagnostics & research

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends